Overview
EVMN market data
Price History
EVMN price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for EVMN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26Benzinga · Jun 30, 2026, 1:00 PM
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For TuesdayBenzinga · Jun 30, 2026, 12:55 PM
William Blair Downgrades Evommune to Market PerformBenzinga · Jun 29, 2026, 4:55 PM
Evommune's Skin Disorder Study Falls ShortBenzinga · Jun 29, 2026, 4:40 PM
Crude Oil Gains 2%; Comcast Shares Spike HigherBenzinga · Jun 29, 2026, 4:35 PM
Nasdaq Jumps More Than 1%; Comcast Shares Spike HigherBenzinga · Jun 29, 2026, 1:45 PM
Evommune Announces Its Phase 2b Study Of EVO756 Oral Antagonist Failed To Meet Primary Endpoint Of Average Change In Participant's Urticaria Activity Score Over 7 Days At 12 WeeksBenzinga · Jun 29, 2026, 12:40 PM
8-K filing — Evommune, Inc. (EVMN)SEC EDGAR · Jun 29, 2026, 12:32 PM
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · Jun 29, 2026, 12:15 PM
HC Wainwright & Co. Reiterates Buy on Evommune, Maintains $50 Price TargetBenzinga · May 26, 2026, 10:53 AM